 Connection
Aravindhan Veerapandiyan to Dependovirus
This is a "connection" page, showing publications Aravindhan Veerapandiyan has written about Dependovirus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.497 |
|
|
|
-
Shieh PB, Proud C, Diamond T, Chapin CA, Ahmad J, Salama AD, B?nnemann CG, Soslow J, Byrne BJ, Veerapandiyan A, Brandsema JF, Matesanz S, Samelson-Jones BJ, Wilkins BJ, Gerber M, Godwin Wild KE, Mason S, Asher D, McDonald CM, Mendell JR. Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management. Hum Gene Ther. 2026 Mar; 37(5-6):262-279.
Score: 0.230
-
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025 Jan; 31(1):332-341.
Score: 0.209
-
Muntoni F, Nascimento A, Shin J, Guglieri M, Stettner GM, Veerapandiyan A, Gallo S, Shi H, Gundapaneni B, Neelakantan S, Lobello K, Shen Q, Levy DI, Mercuri E. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2026 Mar; 25(3):245-255.
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|